SFRT+Tislelizumab+Platinum Chemotherapy for Unresectable Stage III NSCLC

The aim of this clinical trial is to understand whether spatial fractionated radiotherapy (SFRT) in combination with tislelizumab and platinum-based doublet chemotherapy given concurrently as induction treatment is effective in treating initially unresectable stage Ⅲ non-small cell lung cancer (NSCLC). It will also explore the safety of this treatment modality. The main questions it aims to answer are: Will spatial fractionated radiotherapy (SFRT) in combination with tislelizumab and platinum-based doublet chemotherapy given concurrently as induction treatment increase the surgical resection

Trial Details

NCT ID
NCT07131319
Phase
PHASE2 / PHASE3
Sponsor
Second Affiliated Hospital of Nanchang University
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Spatially Fractionated Radiotherapy (SFRT)
  • Tislelizumab, Carboplatin, Pemetrexed
  • Tislelizumab, paclitaxel, Carboplatin
Locations (sample)
  • Nanchang, Jiangxi, China|28.68396,115.85306

Key Eligibility Criteria

  • The patient has histologically or cytologically confirmed stage III non-small cell lung cancer (NSCLC) that is deemed unresectable after discussion…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →